All News | RheumNow

All News

JIA.oligoarticular.jpg

MMWR: Arthritis Among Children and Adolescents

Save

d Jack Cush, MD

Jul 21, 2023

The CDC estimates that nearly 220,000 children and adolescents had arthritis during 2017–2021.

Read Article

RheumNow Podcast square

"Ask Cush Anything" Returns (7.21.2023)

Save

d Jack Cush, MD

Jul 21, 2023

Dr. Jack Cush reviews the news and journal reports and this week, takes on 5 cases/questions from "Ask Cush Anything"

Read Article

Tofactitinib in PsA & RA: Nine Year Safety Data

Save

d Jack Cush, MD

Jul 20, 2023

Tofacitinib is FDA approved for psoriatic arthritis and rheumatoid arthritis, but long term safety outcomes beyond a year are limited. A real-world, post-marketing surveillance of tofacitinib in PsA and RA shows a consistent pattern of safety with no new safety concerns identified.

Read Article

glomerulonephritis.GN_.lupus_.jpg

Voclosporin in SLE - Long-Term Safety and Efficacy

Save

d Jack Cush, MD

Jul 20, 2023

The AURORA 2 study evaluated the long-term safety and efficacy of voclosporin lupus nephritis patients and, after three years, demonstrated long term safety and efficacy following the one-year AURORA 1 study.

Read Article

infx.pneumonia.jpg

Infectious Risk with B Cell Therapies in Lupus

Save

d Jack Cush, MD

Jul 19, 2023

A UK registry study of moderate to severe systemic lupus erythematosus (SLE) patients showed that treatment with rituximab or belimumab was not associated with a greater risk of serious infection, when compared to standard of care therapy.

Read Article

RNase

RNase Treatment of Autoimmune Disorders

Save

d Jack Cush, MD

Jul 19, 2023

U1RNP complex, Ro/SSA and La/SSB are major RNA-containing autoantigens associated with autoimmune disorders. Immune complexes (ICs) composed of RNA-containing autoantigens and autoantibodies are suspected to be involved in the pathogenesis of some systemic autoimmune diseases.

Read Article

Plaquenil.HCQ_.pills_.jpg (keep)

Danger with Hydroxychloroquine Nonadherence in SLE

Save

d Jack Cush, MD

Jul 18, 2023

A large cohort study shows that severe non-adherence to hydroxychloroquine (HCQ) results in serious risks for SLE flares, damage, and mortality.

Read Article

Words of wisdom from Dr. Bharat Kumar, editor of the Rheumatologist @BharatKumarMD https://t.co/VbgI9ew5T8

Dr. John Cush RheumNow ( View Tweet)

Jul 21, 2023

Cohort comparison of Psoriatic arthritis in 141 males vs 131 females: found psoriasis (BMI , BSA) was worse in males, but PsA worse in females (higher PtGA, PtPnV, TJC, SJC, DAPSA, HAQ-DI, and PsAID-12). Men more likely to get to MDA than females https://t.co/e1mFo0kCtL https://t.co/LfJJZc5Ecp

Links:

https://bit.ly/3NZPkzp

Dr. John Cush RheumNow ( View Tweet)

Jul 21, 2023

Study of >19K RA pts in National Databank showed that Opioids vs NSAID use had similar MACE risk(20.6 vs 18.9/1000 PY), but opioids had higher mortality (13.5 vs 10.8/1000 PY; HR1.33) & VTE risk(HR=1.41). Opioids are not safer than NSAIDs https://t.co/J56BqYMKM1 https://t.co/xiz4GGUnJC

Links:

https://bit.ly/3Q2ev71

Dr. John Cush RheumNow ( View Tweet)

Jul 20, 2023

BE OPTIMAL study: Bimekizumab vs adalumumab in 702 #PsA pts, showed sustained 52 week ACR50 responses at wk 52: 54% BKZ v 50% ADA; PASI 100 61% BKZ v 48% ADA. Serious AE seen in 6.6% of BKZ patients, 1 death and 7.7% w/ Candida (vs 0.7% w/ ADA) https://t.co/4g3j5OoKyy https://t.co/g4SQubSCXg

Links:

https://bit.ly/3rGd4B0

Dr. John Cush RheumNow ( View Tweet)

Jul 20, 2023

JAMA has a review of "Diagnosis and Treatment of Hip and Knee Osteoarthritis". Affecting 240 million people worldwide, >32 million in the US. OA Risk factors include age, female, obesity, genetics, & trauma/injury. OA pts have more comorbidities https://t.co/ee10MKIqUp https://t.co/N2i3VWgvc9

Links:

https://bit.ly/3rrUOva

Dr. John Cush RheumNow ( View Tweet)

Jul 20, 2023

Danger with Hydroxychloroquine Nonadherence in SLE A large cohort study shows that severe non-adherence to hydroxychloroquine (HCQ) results in serious risks for SLE flares, damage, and mortality. https://t.co/RFPQZXQMeI https://t.co/eu1rhVyV18

Links:

https://bit.ly/3NXiP56

Dr. John Cush RheumNow ( View Tweet)

Jul 20, 2023

SLE and Pregnancy Outcomes Obstetric complications and poor pregnancy outcomes are not uncommon in women with systemic lupus erythematosus (SLE), especially with active disease. https://t.co/BeCQYTq928 https://t.co/M6oILWfah1

Links:

https://bit.ly/3K5BKt0

Dr. John Cush RheumNow ( View Tweet)

Jul 19, 2023

EULAR Points to Consider in Progressing Psoriasis to Psoriatic Arthritis The transition from psoriasis to PsA – and the early diagnosis of PsA – is of considerable scientific and clinical interest. https://t.co/KYLBU3E0k6 https://t.co/oHgqEX8Gr6

Links:

https://bit.ly/3NXEwSr

Dr. John Cush RheumNow ( View Tweet)

Jul 19, 2023

Belgian study of 312 PsA & 213 SpA pts showed that most had normal spinal Xrays (87.5% PsA, 92% SpA). SpA pts had higher mSASSS than PsA (p<0.05). More Cx (73%) than Lumbar (33%) in PsA; SpA, CX (64%) & LS (71%) evenly distributed https://t.co/Z8JRRuxmWZ https://t.co/8uMiAsk7aA

Links:

https://bit.ly/46X512U

Dr. John Cush RheumNow ( View Tweet)

Jul 19, 2023

Plantar Fasciitis study of 180 PF patients shows no clinically meaningful difference between pts treated with patient advice plus heel cup alone (PA) versus PA and lower limb exercise (PAX) versus PAX plus corticosteroid injection (PAXI) https://t.co/j4Cd42akx6 https://t.co/rQ6vZRw34A

Links:

https://bit.ly/44x56sL

Dr. John Cush RheumNow ( View Tweet)

Jul 19, 2023

Post hoc analysis 2 phase III RCTs of abatacept (Sc & IV) in 409 polyarticular JIA pcJIA. ABA was effective (by JIA-ACR and JADAS27 responses) & well tolerated, regardless of concomitant or prior MTX use. https://t.co/cTn52V5Fuu https://t.co/CUqin00LZh

Links:

https://bit.ly/3Okp3x6

Dr. John Cush RheumNow ( View Tweet)

Jul 19, 2023

Combination Cannabidiol (CBD) & hydroxychloroquine in RA? A phase II trial of IHL-675A (CBD+HCQ) will soon begin; following on phase I and animal studies showing it was tolerated, with no adverse events of concern.IHL-675A was superior to HCQ alone. https://t.co/HZYR7FA7i1 https://t.co/jvlot0OIw4

Links:

https://bit.ly/3K68PFj

Dr. John Cush RheumNow ( View Tweet)

Jul 18, 2023

Nonprofit Allen Institute for Immunology will partner with researchers from Eli Lilly to investigate and profile disease state diversity and biomarkers for drug response in atopic dermatitis and rheumatoid arthritis https://t.co/nRbdWdFx7C https://t.co/rlngbtxgUo

Links:

https://bit.ly/3NVNm2Z

Dr. John Cush RheumNow ( View Tweet)

Jul 18, 2023

×